Home
- Belegger.nl: steun en toeverlaat voor beleggers. Bekijk de beurskoersen, de laatste stand van de AEX en lees het nieuws, de columns en de adviezen.
Koersen
- Aandelen
- Indices
- Valutas
- Rentes
- Commodities
- Certificaten
- Opties
- Futures
- Beleggingsfondsen
- Trackers
- Obligaties
- Hefboomproducten
Nieuws
Forum
Analyse & advies
Thema's
- Beurstips en handelskansen
- Fondsen & ETF's

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX: Euronext Amsterdam
BRU: Euronext Brussels
PSE: Euronext Paris
LIS: Euronext Lissabon
CHX: CBOE Europe, grote(re) EU aandelen
NAV: Investment Funds (NAV)

Noord-Amerika

NYS: New York Stock Exchange
OTC: CBOE BZX Exchange (US)
TSE: Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

Market Monitor

BioPharma « Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 9

2.021 Posts, Pagina: « 1 2 3 4 5 6 ... 59 60 61 62 63 64 65 66 67 68 69 ... 98 99 100 101 102 » | Laatste

Omlaag ↓

[verwijderd] 9 juli 2007 15:09

sky nog 20 minuten rammen ze hem wel weer terug

orchid 9 juli 2007 15:10

09:08 $ 1.23 300
09:08 $ 1.23 100
08:40 $ 1.28 2,000
08:39 $ 1.28 100

voor wat het waard is, in ieder geval beweging boven de 1,2

[verwijderd] 9 juli 2007 15:12

1,28 geweest stel je toch eens voor :lol

[verwijderd] 9 juli 2007 15:16

De koers dreigt te exploderen!

[verwijderd] 9 juli 2007 15:20

ATryn® INTRODUCED AT INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIS CONGRESS

GENEVA, Switzerland – July 9, 2007 – GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and LEO Pharma A/S announced today that ATryn®, the first recombinant human antithrombin therapeutic and the first transgenically produced drug, is being introduced to the international medical community at the International Society on Thrombosis and Haemostasis, or ISTH, Bi-Annual Meeting. ATryn® is being commercialized and further developed in Europe by LEO, GTC’s development and commercialization partner in Europe, Canada and the Middle East.

The Congress is taking place in Geneva, Switzerland from July 6 through July 12. ATryn® related events at ISTH include:

Two posters by R. Campbell Tait, MD, Glasgow Royal Infirmary, et al, presented by Johan Frieling, MD, Ph.D, GTC Consulting Medical Director, describing dosing strategies for managing antithrombin levels in patients with hereditary antithrombin deficiency undergoing surgery or delivery, procedures that are associated with a high risk for developing a thromboembolism.
A scientific symposium moderated by Mario von Depka, MD, Ph.D Director, Werlhof Institute for Thrombosis and Haemostasis, Hannover, Germany entitled, “ATryn®, The First Recombinant Antithrombin: Innovation or Alternative?” The symposium includes presentations and a panel discussion with Dr. von Depka (clinical data), Dr. Harry Meade, Sr. Vice President, Research, GTC, (transgenic technology), and Dr. Carol Ziomek, Vice President, Development, GTC, (product purity).
A press conference and panel discussion on Monday, July 9 (Room F) hosted by Geoffrey Cox, Ph.D, Chairman, President and CEO, GTC Biotherapeutics, titled, “Recombinant Antithrombin: Clinical Opportunities from Transgenic Production.” Panel members include Dr. von Depka, Dr. Meade, and Dr. Ziomek.
Anexhibition booth hosted by LEO. LEO anticipates sales of ATryn® as reimbursement prices are established on a country-by-country basis through the remainder of 2007 and into 2008.

Antithrombin, produced in the liver and circulated in blood plasma, has both anticoagulant and anti-inflammatory properties. The recombinant form is produced using GTC’s transgenic production platform, enabling large volume supply of antithrombin.

ATryn® has been approved for use in Europe for the prophylactic treatment of venous thromboembolism in hereditary antithrombin deficient patients undergoing surgical procedures. GTC is in comparative Phase III studies for a similar indication, including pregnant patients, in the United States. These studies include an evaluation of the incidence of thromboembolism in 17 hereditary antithrombin deficient patients undergoing surgery and pregnancy, andwill be compared with the historical records of at least 35 patients who have undergone similar procedures but who were treated with plasma-derived antithrombin products. GTC plans to release data from this research in the fourth quarter of 2007.

Separately, LEO is initiating a Phase II dose-ranging study ofATryn® in disseminated intravascular coagulation, or DIC, associated with severe sepsis. The first patient to be treated in this study is expected to be dosed soon. DIC associated with severe sepsis represents a significant unmet medical need in both the United States and Europe, affecting approximately 500,000 patients per year with mortality rates reaching 50%. GTC will have access to the Phase II data for use in the United States and the rest of the world.

About ISTH

The International Society on Thrombosis and Haemostasis, Inc. is organized and operated exclusively for scientific and educational purposes. Its objectives are to foster and advance science relating to the important medical problems of thrombosis and abnormalities of hemostasis and vascular biology; to provide a forum for discussion of these problems; to encourage research on these problems by scientists of the several relevant disciplines; to foster the diffusion and exchange of ideas through scientific meetings and publications; and to standardize nomenclature and methods as appropriate and timely.

About LEO Pharma

LEO Pharma is an independent research based pharmaceutical company with headquarters located in Ballerup, Denmark. LEO Pharma is 100% owned by the LEO Foundation and is one of the world’s leading companies in dermatology and thromboembolism. LEO Pharma discovers, develops and manufactures safe and efficacious drugs and markets them globally – 96% of revenues are generated outside of Denmark. LEO Pharma is represented in more than 90 countries and has around 3,000 employees around the world; 1,200 of these in Denmark. www.leo-pharma.com

About GTC Biotherapeutics

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn® is both the first therapeutic product produced by transgenic technology to obtain regulatory approval anywhere in the world and the first recombinant antithrombin product. ATryn® is produced in goats that have the human antithrombin gene linked to a milk-protein promoting gene so that they express this protein in their milk. This transgenic approach provides the opportunity to produce recombinant forms of proteins, such as antithrombin, that are difficult to express in economically viable quantities in conventional production systems.

In addition, GTC has established a strategic collaboration with LFB Biotechnologies of France to jointly develop recombinant forms of human plasma proteins and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia in patients with antibodies to other coagulation factors.

In 2006, GTC was granted a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, www.gtc-bio.com.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding prospects for clinical development ofATryn®and its market launch in selected European countries. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC's most recent Annual Report on Form 10-K and its other periodic reports filed with the Securities and Exchange Commission, including the uncertainties associated with conducting clinical studies, and the risks and uncertainties associated with dependence upon the actions of collaboration partners and regulatory agencies. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to u

[verwijderd] 9 juli 2007 15:20

quote:
larsenterry schreef:
De koers dreigt te exploderen!

Denk het niet, oharme 5K voorbeurs. Alhoewel je zou denken dat het toch één van die PR's zijn waar we op zitten te wachten!!
Maar koers doet weer géén malle moer,
begrijpe, wie begrijpe kan!!

[verwijderd] 9 juli 2007 15:36

WOW mn $1.23 koersalert binnen.

Ff afwachten,gaan we werkelijk...dan wil ik wel bijkopen.

Vreemd trouwens,nu met slechts 80K door de o zo taaie 1.20 heen.

[verwijderd] 9 juli 2007 15:38

eerst weerstand 1.23 breaken....

print.chartnet.nl/Show.cgi?Img=92A95E...

[verwijderd] 9 juli 2007 15:39

quote:
SkySpam1 schreef:
[quote=larsenterry]
De koers dreigt te exploderen!

[/quote]

Denk het niet, oharme 5K voorbeurs. Alhoewel je zou denken dat het toch één van die PR's zijn waar we op zitten te wachten!!
Maar koers doet weer géén malle moer,
begrijpe, wie begrijpe kan!!

De koers van Univar is vandaag hetzelfde vakkundige horizontale streepje als dat we maanden bij GTCB zien. Vakkundig of koud kunstje? Bij Univar werd de aandeelhouder ook helemaal gek gemaakt met onverklaarbare bokkensprongen in de koersvorming.

ludwig mack 9 juli 2007 15:39

Laatste 1,22 15:37 100
+/- 0,02 1,67%
Open 1,21 15:30
Slot 1,20 6/7
Hoog 1,23 15:31
Laag 1,21 15:30
Volume 74.772

[verwijderd] 9 juli 2007 15:46

Pff Het hoogtepunt alweer gehad zeker...

Bij $1.24 maar weer ff kijken,mocht deze komen.
Veels te laag volume om werkelijk de weg naar boven in te slaan.
Al zag de opening er veelbelovend uit.

[verwijderd] 9 juli 2007 15:51

quote:
SkySpam1 schreef:
De bied bevindt zich zowaar boven de $1.20!!

Gaan we nu eindelijk boven de $1.20 openen, en er dan ook nog blijven.

Ik hoop ramon, dat je nou net niet, iets te vroeg verkocht hebt.

Bezit nog voldoende om mee te profiteren Sky.
En zoals eerder aangegeven,gaat die werkelijk dan koop ik mn oude stukken duurder terug.
Kijk niet op een paar centen per aandeel in dat geval.

Succes

[verwijderd] 9 juli 2007 16:14

De bied op $1.21 begint aardig op te lopen.

RT $1.21

orchid 9 juli 2007 16:18

ach, hoe je het ook ziet, er is wat leven in de brouwerij, als we boven de 1,2 sluiten is dat al een enorme trendbreuk :)

de rest van de beurs doet het geweldig, tijd voor een koud biertje.

ludwig mack 9 juli 2007 16:22

we stellen ons er te veel van voor, maar ze krijgen nu in ieder geval betalingen van leo en stijgt de koers nu niet als een gek, straks bij de cijfers zeker ........ en de eerste ramingen van verkopen!

[verwijderd] 9 juli 2007 17:24

News is out en koers doet niets. Logisch omdat we dit nieuws feit al jaren wisten.

[verwijderd] 9 juli 2007 17:28

ligt weer een ijsberg op 1.22 volgens mij

[verwijderd] 9 juli 2007 17:29

Posted by: read_this_n0w
In reply to: None Date:7/9/2007 11:00:55 AM
Post #of 4063

"LEO anticipates sales of ATryn® as reimbursement prices are established on a country-by-country basis through the remainder of 2007 and into 2008. "

Thats a delay from the initial timeline, is it not?

[verwijderd] 9 juli 2007 17:35

Dat is negatief news. Dalen maar weer ? Koop kansen ? Hét bericht is natuurlijk fda goedkeuring.

[verwijderd] 9 juli 2007 17:36

lees het eerder dat ieder land stap voor stap gaat

2.021 Posts, Pagina: « 1 2 3 4 5 6 ... 59 60 61 62 63 64 65 66 67 68 69 ... 98 99 100 101 102 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Direct naar Forum

Markt vandaag

AEX	910,59	+6,38	+0,71%	10 mei
AMX	937,23	-0,72	-0,08%	10 mei
ASCX	1.205,64	+11,91	+1,00%	10 mei
BEL 20	4.013,33	+27,93	+0,70%	10 mei
Germany40^	18.773,50	+0,65	+0,00%	10 mei
US30^	39.507,00	0,00	0,00%	10 mei
US500^	5.221,51	0,00	0,00%	10 mei
Nasd100^	18.156,80	0,00	0,00%	10 mei
Japan225^	38.190,30	0,00	0,00%	10 mei
WTI	78,28	0,00	0,00%	10 mei
Brent	82,79	0,00	0,00%	10 mei
EUR/USD	1,0769	-0,0002	-0,02%	02:24
BTC/USD	61.536,00	-1.047,81	-1,67%	02:24
Gold spot	2.362,29	+1,57	+0,07%	02:24